PPT-CV Risk Management in T2DM: What Did We Learn From EASD 2016?

Program Overview EMPAREG OUTCOME Trial Design EMPAREG OUTCOME Primary Endpoint 3Point MACE EMPAREG OUTCOME CV Death EMPAREG OUTCOME CV Death Nonfatal MI and Nonfatal Stroke EMPAREG OUTCOME . Chapter 4. Jean-Marie . Ekoé. , . Zubin. . Punthakee. , Thomas Ransom, . Ally . PH . Prebtani. , Ron Goldenberg. Canadian Diabetes Association 2013 Clinical Practice Guidelines. Screening Checklist. T2DM patients. Marwan Ahmed. Dr. George . Muntingh. Prof Paul . Rheeder. Background. Metformin is the cornerstone therapy in the management of . T2DM. It is routinely prescribed to 120 . million diabetic . Chapter 5. Thomas . Ransom, Ronald Goldenberg, Amanda . Mikalachki. , Ally . PH . Prebtani. , . Zubin. . Punthakee. Canadian Diabetes Association 2013 Clinical Practice Guidelines. Key Points. At this time, there are no safe and effective strategies to prevent T1DM. Naushira. Pandya M.D., CMD, FACP. M.. . NaushiPandyM.DM. Professor and Chair. Department of Geriatrics. Director, Geriatrics Education Center. Nova Southeastern University College of Osteopathic . Medicine. Program Goal. Case Presentation: Diane. Case Presentation (cont). ADA/EASD Position Statement. ADA/EASD Position Statement: Glycemic Targets. ADA/EASD Position Statement on Therapeutic Options: Lifestyle. Disease. . s_khalilzadeh. A Novel. Cardiometabolic Risk Factor for Type 2 Diabetes. NAFLD and T2DM. NAFLD is closely associated with features of the metabolic. syndrome and is regarded as the hepatic manifestation. Prediabetes. Consensus Statement: Summary. Untreated individuals with . prediabetes. are at increased risk for diabetes as well as for micro- and . macrovascular. complications. Treatment goals are to prevent deterioration in glucose levels and modify other risk factors such as obesity, hypertension, and dyslipidemia . Obesity and T2DM. Introduction/Overview . Obesity. and T2DM: Key Correlations. Improvements in Metabolic Parameters Pre- . a. nd Post-Roux-en-Y Surgery. Post-Hoc Analysis Look AHEAD: The Importance of ≥ 10% Weight Loss. T2DM 1. Cyto. T2DM 5. Cyto. ND 4. Cyto. ND 5. Cyto. T2DM 6. Cyto. ND 3. Cyto. T2DM 4. Cyto. ND 1. Cyto. ND 6. Cyto. T2DM 2. Mito ND 1. Mito T2DM 1. Mito T2DM 6. Mito ND 2. Mito T2DM 4. Mito T2DM 2. The . aim . of the association . is . to encourage and support research in the field of diabetes, the rapid diffusion of acquired knowledge and to facilitate its application. CVOT-based ADA/EASD . recommendations 2020. Treatment of T2DM. A.Amouzegar. , MD. Endocrine Research Center, . Research Institute for Endocrine . sciences. 12.2.98. Agenda. Review ADA guideline . Case presentations. Conclusion. Patient-Centric Focus of 2016 . Backgrounde International Diabetes Federation (IDF) estimates that worldwide, 415 million people have diabetes, 91% of whom have type 2 diabetes mellitus (T2DM) []. People with diabetes comprise 8.8% kindly visit us at www.examsdump.com. Prepare your certification exams with real time Certification Questions & Answers verified by experienced professionals! We make your certification journey easier as we provide you learning materials to help you to pass your exams from the first try. Professionally researched by Certified Trainers,our preparation materials contribute to industryshighest-99.6% pass rate among our customers. Research Institute for Endocrine Sciences. Shahid. . Beheshti. University of Medical Sciences. 21 July 2016. Nonalcoholic Fatty Liver Disease . Case Discussion . 2. Case 1. Case 1. A generally healthy 42 y/o lady came to you for evaluation of fatty liver (grade I) discovered during a routine abdominal ultrasound..